SMi presents the 13th annual industry leading conference: Cold Chain Distribution

SMi Group10 - 11 December 2018, London, UK.
The 13th annual event will specifically focus on recent advances in temperature-controlled logistic solutions and the impact of regulatory changes on this multi-billion-dollar industry. The event will also address the impact of the overwhelming digitalisation of the industry and how companies, from biotech’s to pharma, need to adapt, as well as the crucial challenges of supply chain visibility and data integrity in the cold chain industry.

The two-day event will also look at various developments within the industry, guiding companies on how best to ensure costs are kept low, and quality remains high, whilst simultaneously staying compliant to global regulations.

This year's event will continue to lead with its unrivalled panel of experts bringing you the most insightful presentations and issues in the field of temperature-controlled distribution.

Chairs for 2018

  • Bob Hayes, Director, SeerPharma (UK)
  • Tony Wright, CEO, Exelsius

Featured Speakers

  • Bob Hayes, Director, SeerPharma (UK)
  • Stephen Mitchell, Quality Lead Logistics Partnerships, GSK
  • GianneOlaes-Dénis, Supply Chain Quality Manager, SanofiGenzymeEurope
  • Stefan Braun, Managing Director, SmartCAE
  • GianpieroLorusso, Director, Supply Operations and GS, Merck
  • Francicso Rizzuto, Cargo Specialist, Manager for Europe, IATA
  • Marco Gaudesi, Pharmacist - GDP and Cold Chain Referent, MSF
  • Henk Mulder, Head, Digital Cargo, IATA

Key Highlights

  • Evaluate the current GDP guidelines, with reference to the recently published PQG/ECA guide and discover the implications for everyday practice
  • Explore the overwhelming digitalisation of the supply chain and identify the subsequent security issues involved
  • Discover the temperature-controlled logistic solutions to best optimize your supply chain
  • Discuss the technical agreements within the supply chain and find out what questions you should be asking
  • Identify the challenges for the supply chain within emerging markets and discover the best solutions for optimization of your process

View the full agenda online: www.coldchain-distribution.com

  • Register by 29th June and save £400
  • Register by 28th September and save £300
  • Register by 31st October and save £200

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Most Popular Now

COVID-19 Long-Acting AntiBody (LAAB) combination A…

AstraZeneca's long-acting antibody (LAAB) combination, AZD7442, will advance into two Phase III clinical trials in more than 6,000 participants at sites in and outside th...

Johnson & Johnson announces European Commissio…

Johnson & Johnson (NYSE: JNJ) (the Company) announced the European Commission (EC), acting on behalf of the European Union (EU) Member States, has approved an Advance Pur...

BioNTech and Pfizer initiate rolling submission to…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the initiation of a rolling submission to the European Medicines Agency (EMA) for BNT162b2, the lea...

Vir Biotechnology and GSK announce global expansio…

Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) announced the global expansion to Phase 3 of the COMET-ICE (COVID-19 Monoclonal antibody Eff...

Johnson & Johnson initiates pivotal global Pha…

Johnson & Johnson (NYSE: JNJ) (the Company) announced the launch of its large-scale, pivotal, multi-country Phase 3 trial (ENSEMBLE) for its COVID-19 vaccine candidate, J...

Regeneron's REGN-COV2 antibody cocktail reduced vi…

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced the first data from a descriptive analysis of a seamless Phase 1/2/3 trial of its investigational antibody cockta...

Gilead Sciences signs joint procurement agreement …

Gilead Sciences (Nasdaq: GILD) and the European Commission signed a joint procurement agreement (JPA) that will enable rapid and equitable access to Veklury® (remdesivir)...

COVID-19 vaccine AZD1222 clinical trial resumed in…

The Phase I/II clinical trial for the COVID-19 vaccine AZD1222 has resumed in Japan after discussion with the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). ...

Popular COVID-19 conspiracies linked to vaccine 'h…

A new study of beliefs and attitudes toward COVID-19 in five different countries - UK, US, Ireland, Mexico and Spain - has identified how much traction some prominent con...

Scientists identify common vulnerabilities across …

In a study published online in Science, an international team of almost 200 researchers from 14 leading institutions in six countries, including France with the Institut ...

Sanofi and Translate Bio mRNA COVID-19 vaccine can…

Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, today announced...

Potential COVID-19 vaccines not affected by domina…

Vaccines currently being developed for COVID-19 should not be affected by recent mutations in the virus, according to a new study involving a University of York virologis...